COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have prompted investigators to implement novel clinical trials which combine immunotherapy with different treatment modalities. Moreover is also important to investigate the mechanisms which regulate the dynamic expression of PD-L1 on tumor cells and PD-1 on T cells in order to identify predictive biomarkers of response. COX-2 is currently investigated as a major player of tumor progression in several type of malignancies including melanoma. In the present study we investigated the potential relationship between COX-2 and PD-L1 expression in melanoma. Tumor samples obtained from primary melanoma lesions and not matched lymph node metastases were analyzed for both PD-L1 and COX-2 expression by IHC analysis. Status of BRAF and NRAS mutations was analyzed by sequencing and PCR. Co-localization of PD-L1 and COX-2 expression was analyzed by double fluorescence staining. Lastly the BRAF V600E A375 and NRAS Q61R SK-MEL-2 melanoma cell lines were used to evaluate the effect of COX-2 inhibition by celecoxib on expression of PD-L1 in vitro. BRAF V600E/V600K and NRAS Q61R/Q61L were detected in 57.8 and 8.9% of the metastatic lesions, and in 65.9 and 6.8% of the primary tumors, respectively. PD-L1 and COX-2 expression were heterogeneously expressed in both primary melanoma lesions and not matched lymph node metastases. A significantly lower number of PD-L1 negative lesions was found in primary tumors as compared to not matched metastatic lesions ( P = 0.002). COX-2 expression significantly correlated with PD-L1 expression in both primary ( P = 0.001) and not matched metastatic ( P = 0.048) lesions. Furthermore, in melanoma tumors, cancer cells expressing a higher levels of COX-2 also co-expressed a higher level of PD-L1. Lastly, inhibition of COX-2 activity by celecoxib down-regulated the expression of PD-L1 in both BRAF V600E A375 and NRAS Q61R SK-MEL-2 melanoma cell lines. COX-2 expression correlates with and modulates PD-L1 expression in melanoma cells. These findings have clinical relevance since they provide a rationale to implement novel clinical trials to test COX-2 inhibition as a potential treatment to prevent melanoma progression and immune evasion as well as to enhance the anti-tumor activity of PD-1/PD-L1 based immunotherapy for the treatment of melanoma patients with or without BRAF/NRAS mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Down-regulation of PD-L1 by celecoxib in BRAFV600E and NRASQ61R melanoma cell lines. BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. a Following a 24 h incubation at 37 °C in a 5% CO2 atmosphere, cells were harvested and lysed. Cell lysates were analyzed by western blot with the indicated mAbs. PD-L1 was detected using the PD-L1-specific mAb (clone SP-142). GAPDH was used as a loading control. Representative results are shown (upper panel). The levels of PD-L1 normalized to GAPDH are plotted and expressed as mean ± SD of the results obtained in three independent experiments (bottom panel). *** indicate P < 0.001. b Following a 24 h incubation at 37 °C in a 5% CO2 atmosphere, cells were harvested and cell surface stained with the PE-conjugated PD-L1-specific mouse mAb [clone MIH1 (RUO)]. PE-conjugated mouse IgG1 was used as a specificity control. Representative results are shown](https://figures.cochat.ai/paper-figures/63f8a39ac33b4b87885f9777159618fb/cox-2-expression-positively-correlates-with-pd-l1-expression-in-human-melanoma-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cyclooxygenase-2 (COX-2) expression is also correlates with PD-L1 expression in primary melanomas, and inhibition of COX-2 by celecoxib downregulates PD-L1 in melanoma cells113.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The full coding sequences and splice junctions of NRAS (exons 1 and 2) and the entire sequence of the BRAF (exon 15) [24, 25] were screened for mutations.”
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Trypan Blue Exclusion Test of Cell Viability
Strober, W. (2015) · Current Protocols in Immunology · doi:10.1002/0471142735.ima03bs111 · Cited by 2,597 · cited 1×
“Following a 24 h incubation at 37 °C in a 5% CO2 atmosphere, cell viability was evaluated utilizing the trypan blue assay which was carried out as reported elsewhere [32].”
Cited by
Mechanisms and prevention of UV‐induced melanoma
Sample, A., & He, Y. (2018) · Photodermatology, Photoimmunology & Photomedicine · doi:10.1111/phpp.12329 · Cited by 372
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Self-citationIntratumor and Intertumor Heterogeneity in Melanoma
Grzywa, T. M., Paskal, W., & Włodarski, P. K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.09.007 · Cited by 299
“[154] observed heterogeneous expression of both PD-L1 and COX-2 in primary tumors and lymph node metastases.”
BackgroundCortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Bisonni, R., Santini, D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001361 · Cited by 275
Self-citationCyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells
Jin, K., Qian, C., Lin, J., & Liu, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1099811 · Cited by 182
Metadata
- Authors
- Botti, G., Fratangelo, F., Cerrone, M., Liguori, G., Cantile, M., Anniciello, A. M., Scala, S., D’Alterio, C., Trimarco, C., Ianaro, A., Cirino, G., Caracò, C., Colombino, M., Palmieri, G., Pepe, S., Ascierto, P. A., Sabbatino, F., & Scognamiglio, G.
- Affiliations
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Naples Federico II (IT)
- National Research Council (IT)
- University of Salerno (IT)
- Corresponding author
- Sabbatino, Francesco
- Scognamiglio, Giosuè
- ORCID
- Venue
- Journal of Translational Medicine
- Published
- 2017-02-23
- Volume
- 15
- Issue
- 1
- Pages
- 46-46
- ISSN
- 1479-5876 (ISSN-L)
- PMC
- PMC5324267
- OpenAlex
- W2590837684
- Cited by
- 104
- References
- 64
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 8 · 2023: 13 · 2022: 9 · 2021: 15 · 2020: 20 · 2019: 12 · 2018: 8 · 2017: 5
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Translational Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- OMA, cyclooxygenase-2, PD-L1, PD-1/PD-L1 inhibitors, celecoxib, COX-2 inhibition, BRAF V600E mutation, NRAS Q61R, lymph node metastasis, tumor immune evasion, predictive biomarkers, immunotherapy resistance, A375 cells, protein colocalization
- MeSH terms
- Celecoxib, Humans, Immunohistochemistry, Lymphatic Metastasis, Melanoma, Membrane Proteins, Mutation, Down-Regulation, GTP Phosphohydrolases, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Cell Proliferation, Cyclooxygenase 2, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. https://app.cochat.ai/papers/10.1186/s12967-017-1150-7
- The paper
- Botti, G., Fratangelo, F., Cerrone, M., Liguori, G., Cantile, M., Anniciello, A. M., Scala, S., D’Alterio, C., Trimarco, C., Ianaro, A., Cirino, G., Caracò, C., Colombino, M., Palmieri, G., Pepe, S., Ascierto, P. A., Sabbatino, F., & Scognamiglio, G. (2017). COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. Journal of Translational Medicine. https://doi.org/10.1186/s12967-017-1150-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.